GlassScriptPhysician profile
Jimmie Young
NPI 1326087032
$2,010.70
in general payments reported to CMS, 2019-2025
27 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $110 · 2021: $370 · 2022: $226 · 2023: $348 · 2024: $289 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $265.69 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $243.95 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.74 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $175.47 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Alkermes, INC. | $137.84 | 2021-2025 | Vivitrol, Vivitrol |
| Merck Sharp & Dohme LLC | $131.22 | 2019-2025 | Capvaxive, Gardasil 9 |
| Braeburn INC. | $109.49 | 2023-2025 | Brixadi |
| Kowa Pharmaceuticals America, INC. | $95.89 | 2024-2025 | Zoryve |
| Abbvie INC. | $80.59 | 2021-2022 | |
| Pfizer INC. | $78.20 | 2019-2024 | |
| Glaxosmithkline, LLC. | $61.62 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $58.10 | 2021-2022 | |
| Sanofi Pasteur INC. | $55.40 | 2019-2023 | |
| Amarin Pharma, INC. | $42.27 | 2019 | |
| Amgen INC. | $40.03 | 2019-2025 | Repatha, Repatha |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $28.39 | 2021 | |
| Xeris Pharmaceuticals, INC. | $28.38 | 2022-2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $28.13 | 2021 | |
| Paratek Pharmaceuticals, INC. | $27.67 | 2024 | Nuzyra |
| Indivior INC. | $26.78 | 2019-2025 | Sublocade |
| Qiagen, LLC | $26.26 | 2019-2021 | |
| Insulet Corporation | $23.01 | 2024 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.19 | 2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.85 | 2020 | |
| Medtronic, INC. | $15.08 | 2025 | Minimed 780g |
| Nabriva Therapeutics, Plc | $11.87 | 2020 | |
| Emd Serono, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmie Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.